Promising Results for 61Cu-NuriPro™ in Prostate Cancer Imaging
NUCLIDIUM AG has recently unveiled groundbreaking data from a Phase 1 clinical trial for its innovative PET imaging agent, 61Cu-NuriPro™. This novel imaging agent, specifically designed for detecting metastatic prostate cancer, was presented with great enthusiasm during the Society of Nuclear Medicine & Molecular Imaging (SNMMI) annual meeting. Its capabilities in revealing lesions missed by traditional imaging techniques marks a significant step forward in the field.
Key Findings from the Phase 1 Trial
The data from the trial highlighted that 61Cu-NuriPro™ was able to detect a greater number of lesions by up to four hours post-administration in 50% of patients. This clearly demonstrates its improved efficacy compared to the widely used 18F-piflufolastat PET. Additionally, the dosimetry data showed a favorable tumor-to-background ratio, which is crucial for optimizing imaging clarity during diagnostics.
Safety and Dosimetry Highlights
Interestingly, the safety profile of 61Cu-NuriPro™ was found to be comparable to those of established PSMA tracers. This reassuring finding complements the favorable imaging performances noted during the trial, where the number of detectable lesions grew as time progressed after the agent's administration. The 3.3-hour half-life of 61Cu-NuriPro™ played a pivotal role in enhancing its distribution scope and diagnostic capabilities.
Expert Insights
Dr. Gary Ulaner, MD, PhD, who serves as the Director of Molecular Imaging and Therapy at the Hoag Family Cancer Institute, emphasized that accurate imaging is essential in managing prostate cancer. He described the results from 61Cu-NuriPro™ as demonstrating a solid safety profile alongside excellent imaging standards compared to current practices. Dr. Ulaner expressed optimism about the potential this agent holds for improving diagnostic accuracy and patient care.
NUCLIDIUM’s Commitment to Innovation
Adding to the excitement, Leila Jaafar, PhD, the CEO and co-founder of NUCLIDIUM, remarked that these results further validate their pioneering copper-based theranostics platform. She underscored the clinical promise that 61Cu-NuriPro™ represents as a leading candidate for becoming a highly effective diagnostic tool. With a commitment to safety, sustainability, and scalable solutions, NUCLIDIUM aims to expand its portfolio of copper-based agents to tackle various cancers effectively.
What's Next for NUCLIDIUM?
The journey doesn’t end with the successful trial of 61Cu-NuriPro™. NUCLIDIUM is also advancing its innovative agent 61Cu-TraceNET™, which targets SSTR-positive tumors, and is currently in Phase 1/2a trials for neuroendocrine tumors. Additionally, there are plans for clinical trials involving therapeutics like 67Cu-NuriPro™ and 67Cu-TraceNET™, extending into early enrollment stages soon.
About NUCLIDIUM
NUCLIDIUM AG stands at the forefront of developing next-generation copper-based radiopharmaceuticals aimed at revolutionary cancer diagnosis and treatment. The company leverages the unique properties of copper isotopes — Copper-61 for diagnostics and Copper-67 for therapeutic applications, creating a robust platform poised to tackle existing challenges in radiotheranostics. With its operations based in Switzerland and Germany, NUCLIDIUM combines innovative chemistry with profound clinical expertise to deliver superior theranostic solutions that are scalable and accessible for patients across the globe.
For Further Information
To learn more about NUCLIDIUM AG and its cutting-edge work, those interested can reach out directly:
NUCLIDIUM
Leila Jaafar, CEO
Email: info@nuclidium.com
Investor/Media Contact NUCLIDIUM
Trophic Communications
Stephanie May
Email: nuclidium@trophic.eu
Phone: +49 171 1855682
Frequently Asked Questions
What is 61Cu-NuriPro™?
61Cu-NuriPro™ is an advanced PET imaging agent designed to detect metastatic prostate cancer more effectively than existing options.
What were the key findings from the Phase 1 trial?
The trial indicated significant improvements in lesion detection, with 50% of patients showing additional lesions compared to traditional imaging.
Who presented the trial results?
Dr. Gary Ulaner, MD, PhD, presented the trial results at the SNMMI 2025 Annual Meeting.
What does NUCLIDIUM aim to achieve with its products?
NUCLIDIUM aims to enhance cancer diagnostics and treatment through innovative and effective radiopharmaceuticals.
How can I contact NUCLIDIUM for more information?
For more information, you can contact NUCLIDIUM via email at info@nuclidium.com.
